Article
Oncology
Yao Yu, Javier Villanueva-Meyer, Matthew R. Grimmer, Stephanie Hilz, David A. Solomon, Serah Choi, Michael Wahl, Tali Mazor, Chibo Hong, Anny Shai, Joanna J. Phillips, Bruce H. Wainer, Michael McDermott, Daphne Haas-Kogan, Jennie W. Taylor, Nicholas Butowski, Jennifer L. Clarke, Mitchel S. Berger, Annette M. Molinaro, Susan M. Chang, Joseph F. Costello, Nancy Ann Oberheim Bush
Summary: The study found that hypermutation induced by temozolomide greatly increased the risk of high-grade disease recurrence in low-grade IDH-mutant glioma patients previously treated with TMZ, and was associated with shorter survival after transformation. Tumors with hypermutation were more likely to develop discontiguous foci of disease in the brain and spine.
Article
Cell Biology
Baiwei Zhang, Cheng Xu, Junfeng Liu, Jinsheng Yang, Qinglei Gao, Fei Ye
Summary: The study revealed that NID1 is overexpressed in glioma tissues, and high NID1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients. NID1 could serve as a potential prognostic biomarker and therapeutic target in this patient population.
Article
Health Care Sciences & Services
Luis E. Ayala-Hernandez, Armando Gallegos, Philippe Schucht, Michael Murek, Luis Perez-Romasanta, Juan Belmonte-Beitia, Victor M. Perez-Garcia
Summary: A mathematical model was constructed to study the response of low-grade gliomas to combinations of temozolomide chemotherapy and radiation therapy, showing that concurrent cycles of radiation therapy and temozolomide could provide the best therapeutic efficacy. Computer simulations extended the patient cohort to 3000 virtual patients, with in-silico trials indicating that matching the doses of radiotherapy to those of temozolomide in the first five days of each cycle improved overall survival. This proposed treatment schedule could potentially improve combination treatments in LGGs in a clinical setting.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Shigeo Ohba, Kei Yamashiro, Yuichi Hirose
Summary: Glioblastoma is the most prevalent and lethal brain tumor, with Temozolomide being a commonly used treatment. However, poor prognosis is often due to drug resistance and tumor heterogeneity, leading to identification of resistance mechanisms and potential strategies for overcoming resistance to improve prognosis.
Article
Oncology
Malobika Chakravarty, Piyali Ganguli, Manikanta Murahari, Ram Rup Sarkar, Godefridus Johannes Peters, Y. C. Mayur
Summary: Drug resistance is a critical challenge in the treatment of Glioma. This study proposed three novel Acridone derivative drugs that, when combined with TMZ, showed major tumor cytotoxicity effective in suppressing growth of both drug sensitive and resistant sub-populations of a tumor. The study also developed a mathematical model to explore drug combinations for the treatment of resistant Glioma, showing synergistic effects with TMZ and Acridone derivatives.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Jacob P. Fisher, David C. Adamson
Summary: The standard of care for high-grade gliomas includes surgical resection, radiation therapy, and temozolomide, which have improved patient survival rates. Besides temozolomide, there are several other FDA-approved treatments for HGG, with tumor treatment fields being the only one shown to significantly improve survival rates.
Review
Oncology
Maximilian J. Mair, Marjolein Geurts, Martin J. van den Bent, Anna S. Berghoff
Summary: WHO grade II-III gliomas are rare primary brain tumors with longer median survival compared to grade IV glioblastoma. Treatment involves maximal safe resection and adjuvant therapies, with challenges in conducting clinical trials due to rarity and long follow-up times. The 2016 WHO Classification introduced a molecular diagnostic framework for more homogenous subgroups. Available evidence for adjuvant treatment was generated pre-molecular era, emphasizing the need for further research in this field.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Qiang Gu, Lang Li, Jiahao Yao, Fa-yan Dong, Yifan Gan, Shuhuai Zhou, Xinyu Wang, Xue-feng Wang
Summary: Researchers identified genes associated with temozolomide resistance and studied these genes in glioma patients using databases. They found that the expression of the feature gene DACH1 was downregulated in temozolomide-resistant cells and that silencing DACH1 reduced the sensitivity of tumor cells to temozolomide. Based on these findings, they constructed a risk model for predicting glioma sensitivity to temozolomide and validated the function of the feature gene DACH1.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Jing Chen, Lingjiao Wu, Hanjin Yang, XiaoChen Zhang, SuZhen Xv, Qiong Qian
Summary: This study identified three LGG subtypes related to cell senescence and developed a cell senescence-related risk score (CSRS) model with six genes. Cell senescence was closely associated with unfavorable prognosis in LGG. The CSRS model can predict the prognosis of patients and identify patients who would benefit from immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Pushan Dasgupta, Veerakumar Balasubramanyian, John F. F. de Groot, Nazanin K. K. Majd
Summary: Preclinical models are crucial for understanding glioma biology and developing therapeutics. However, the development of ideal models is challenging due to various factors, such as genetic background, tumor heterogeneity, intact blood-brain barrier, and the tumor microenvironment. In this review, we discuss in vitro and in vivo models of glioma and the challenges involved in developing optimal models.
Article
Oncology
Deborah Y. Park, Martin C. Tom, Yanwen Chen, Surabhi Tewari, Manmeet S. Ahluwalia, Jennifer S. Yu, Samuel T. Chao, John H. Suh, David M. Peereboom, Glen H. J. Stevens, Gene H. Barnett, Lilyana Angelov, Alireza Mohammadi, Thomas Hogan, Courtney Kissel, Brittany Lapin, Isabel Schuermeyer, Michael W. Parsons, Richard Naugle, Erin S. Murphy
Summary: This study evaluated the effects of concurrent temozolomide-based chemoradiation therapy on neurocognitive function in low-grade glioma patients. Patients aged over 40 and with education over 16 years demonstrated superior baseline verbal memory. Overall, neurocognitive function remained stable following the treatment.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Sujie Gu, Zesheng Peng, Yuxi Wu, Yihao Wang, Deqiang Lei, Xiaobing Jiang, Hongyang Zhao, Peng Fu
Summary: Overexpression of COL5A1 in gliomas is associated with disease progression and poor prognosis, while downregulation can inhibit proliferation and migration of tumor cells and increase their sensitivity to temozolomide. Furthermore, genes co-expressed with COL5A1 participate in various pathways and biological processes involved in glioma progression. Additionally, dendritic cells in the tumor microenvironment of gliomas are positively correlated with the expression levels of COL5A1.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Femke F. Siebenga, Hiska L. van der Weide, Floor Gelmers, Sandra E. Rakers, Miranda C. A. Kramer, Anouk van der Hoorn, Roelien H. Enting, Ingeborg Bosma, Rob J. M. Groen, Hanne-Rinck Jeltema, Michiel Wagemakers, Jacoba M. Spikman, Anne M. Buunk
Summary: Patients with LGG show impaired emotion recognition which is not strongly related to specific tumor characteristics or general cognition. Therefore, measuring social cognition with individual neuropsychological assessment of these patients is crucial to inform clinicians about possible impairments and offer appropriate care.
Article
Biochemical Research Methods
Thibault Delobel, Luis E. Ayala-Hernandez, Jesus J. Bosque, Julian Perez-Beteta, Salvador Chulian, Manuel Garcia-Ferrer, Pilar Pinero, Philippe Schucht, Michael Murek, Victor M. Perez-Garcia, Jennifer A. Flegg, Jennifer A. Flegg, James O'Dwyer, Jennifer A. Flegg, James O'Dwyer, Jennifer A. Flegg, James O'Dwyer
Summary: This study developed a mathematical model to investigate the response of low-grade gliomas to TMZ treatment and proposed a new TMZ administration protocol to delay resistance development and improve patient survival. Computational simulations showed that delivering isolated doses during resting periods could achieve better outcomes.
PLOS COMPUTATIONAL BIOLOGY
(2023)
Article
Oncology
Deheng Li, Liangdong Li, Xin Chen, Wentao Yang, Yiqun Cao
Summary: A novel upregulated circRNA, circSERPINE2, was identified in glioblastoma, promoting tumor cell proliferation and progression by sponging miRNAs and enhancing the expression of the anti-apoptosis gene BCL2. This study reveals the biological function and mechanism of circSERPINE2 in glioblastoma progression, suggesting its potential as a therapeutic target.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Oncology
Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.
Article
Oncology
Antoine Seyve, Caroline Dehais, Olivier Chinot, Apolline Djelad, Elisabeth Cohen-Moyal, Charlotte Bronnimann, Carole Gourmelon, Evelyne Emery, Philippe Colin, Mathieu Boone, Elodie Vauleon, Olivier Langlois, Anna-Luisa Di Stefano, Romuald Seizeur, Francois Ghiringhelli, Anne D'Hombres, Loic Feuvret, Jacques Guyotat, Laurent Capelle, Catherine Carpentier, Louis Garnier, Jerome Honnorat, David Meyronet, Karima Mokhtari, Dominique Figarella-Branger, Francois Ducray
Summary: This study investigates the incidence and characteristics of pseudoprogression in isocitrate dehydrogenase-mutant high-grade gliomas (IDHmt HGG). It suggests that pseudoprogression is not only frequent but also frequently misdiagnosed in IDHmt HGG patients. The study highlights the importance of considering pseudoprogression within the first 2 years after radiotherapy.
Article
Oncology
Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, Wolfgang Wick, Alba A. Brandes, Martin J. B. Taphoorn, Michael Platten, Ahmed Idbaih, Paul M. Clement, Matthias Preusser, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller
Summary: This study retrospectively analyzed the incidence of lomustine-induced thrombocytopenia and its impact on treatment exposure and survival in patients with recurrent glioblastoma. The results showed that thrombocytopenia induced by lomustine is a major limitation to adequate exposure to lomustine chemotherapy and is associated with inferior progression-free survival, particularly in patients with MGMT promoter-methylated tumors.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Clinical Neurology
Macarena Villagran-Garcia, Sergio Muniz-Castrillo, Nicolas Lundahl Ciano-Petersen, Alberto Vogrig, Antonio Farina, Marine Villard, Dimitri Psimaras, Agusti Alentorn, David Goncalves, Nicole Fabien, Veronique Rogemond, Bastien Joubert, Jerome Honnorat
Summary: The link between renal cell and bladder cancer and paraneoplastic neurological syndromes (PNS) is rare and uncertain. This study clinically evaluated these associations and found that bladder cancer patients had higher detection rates of high-risk antibodies and higher certainty of PNS diagnosis.
JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
L. Nguyen-Them, A. Alentorn, G. Ahle, C. Soussain, B. Mathon, M. Le Garff Tavernier, C. Houillier, K. Hoang-Xuan
Summary: PCNSL is a highly aggressive non-Hodgkin lymphoma that affects the brain, spinal cord, eyes, and leptomeninges. Early diagnosis is crucial for effective management, but it can be challenging due to misleading radiological presentations, steroid response bias, and contraindications for brain biopsy. In this review, various CSF biomarkers for diagnosis and prognosis of PCNSL will be discussed, highlighting their advantages and limitations.
REVUE NEUROLOGIQUE
(2023)
Article
Pathology
Thiebaud Picart, Delphine Poncet, Marc Barritault, Luc Bauchet, Sonia Zouaoui, Jacques Guyotat, Mathieu Gabut, Frederic Fina, Jerome Honnorat, Dominique Figarella-Branger, Johan Pallud, Francois Ducray, David Meyronet
Summary: The aim of this study was to identify subgroups of cerebellar glioblastoma (cGBM) based on targeted molecular analysis. Eighty-three cGBM cases were included and classified into 6 mutually exclusive subgroups associated with age at diagnosis and prognosis. MAPK pathway-activating alterations were found to be associated with a better outcome.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2023)
Article
Multidisciplinary Sciences
Rana Salam, Alexa Saliou, Franck Bielle, Mathilde Bertrand, Christophe Antoniewski, Catherine Carpentier, Agusti Alentorn, Laurent Capelle, Marc Sanson, Emmanuelle Huillard, Lea Bellenger, Justine Guegan, Isabelle Le Roux
Summary: NRF2 regulates senescence in malignant cells and contributes to glioblastoma progression. Removal of p16(Ink4a)-expressing malignant senescent cells improves the tumor environment and survival of GBM-bearing mice. NRF2 transcription factor plays a key role in determining the senescent phenotype, and senolytic drug therapy may be beneficial for GBM patients.
NATURE COMMUNICATIONS
(2023)
Article
Multidisciplinary Sciences
Sebastien Durand, Marion Bruelle, Fleur Bourdelais, Bigitha Bennychen, Juliana Blin-Gonthier, Caroline Isaac, Aurelia Huyghe, Sylvie Martel, Antoine Seyve, Christophe Vanbelle, Annie Adrait, Yohann Coute, David Meyronet, Frederic Catez, Jean-Jacques Diaz, Fabrice Lavial, Emiliano P. Ricci, Francois Ducray, Mathieu Gabut
Summary: The study reveals that RSL24D1 is highly expressed in both mouse and human pluripotent stem cells and is involved in the biogenesis of 60S subunits. Depletion of RSL24D1 impairs global translation, particularly of pluripotency factors and components from the Polycomb Repressive Complex 2 (PRC2), leading to altered self-renewal and lineage commitment choices in embryonic stem cells.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Ivan Caramanna, Jaap C. Reijneveld, Peter M. van de Ven, Martin van de Bent, Ahmed Idbaih, Wolfgang Wick, Martin J. B. Taphoorn, Linda Dirven, Andrew Bottomley, Martin Klein
Summary: This study evaluated the cognitive awareness of patients with recurrent high-grade glioma (HGG) and found an association between neurocognitive functioning and complaints. The findings suggest that patients' awareness of their neurocognitive limitations should be considered in clinical decision-making and interpretation of patient-reported outcomes (PROs).
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Nicolas Crainic, Julia Furtner, Johan Pallud, Franck Bielle, Giuseppe Lombardi, Roberta Ruda, Ahmed Idbaih
Summary: The 2021 WHO classification has improved the diagnostic criteria for rare glial, neuronal, and glioneuronal tumors. These tumors present challenges in terms of diagnosis and therapeutic management, and require multimodal parameters for accurate diagnosis. Complete resection of the tumor is crucial for treatment, and targeting MAPK pathway abnormalities could be a promising approach for novel drugs.
Review
Oncology
Alessia Pellerino, Robert M. Verdijk, Lucia Nichelli, Nicolaus H. Andratschke, Ahmed Idbaih, Roland Goldbrunner
Summary: The 2021 WHO classification of the CNS Tumors recognizes Peripheral nerve sheath tumors (PNST) as a distinct group with specific characteristics and recommends diagnostic and therapeutic approaches based on limited evidence due to their rarity. Diagnosis is mainly determined by histological analysis and immunohistochemistry, with genetic analysis required for mosaic forms of NF1 and SPS. MRI is the preferred method for assessing tumor extent. Complete resection is the preferred treatment, balancing nerve preservation. Radiotherapy can be omitted in benign and NF-related tumors. Systemic therapy is recommended for incompletely resected plexiform neurofibromas/MPNSTs, with MEK inhibitors and anthracycline-based treatment being potential options. Clinical trials on MEK1-2 inhibitors and mTOR inhibitors are underway for plexiform neurofibromas and MPNST, respectively.
Review
Biochemistry & Molecular Biology
Agusti Alentorn, Giulia Berzero, Harry Alexopoulos, John Tzartos, German Reyes Botero, Andrea Morales Martinez, Sergio Muniz-Castrillo, Alberto Vogrig, Bastien Joubert, Francisco Garcia A. Jimenez, Dagoberto Cabrera, Jose Vladimir Tobon, Carolina Delgado, Patricio Sandoval, Monica Troncoso, Lorna Galleguillos, Marine Giry, Marion Benazra, Isaias Hernandez Verdin, Maelle Dade, Geraldine Picard, Veronique Rogemond, Nicolas Weiss, Marinos C. Dalakas, Pierre-Yves Boelle, Jean-Yves Delattre, Jerome Honnorat, Dimitri Psimaras
Summary: Anti-NMDAR encephalitis is associated with multiple antigenic triggers and this study aimed to explore if geographic and climatic factors may influence disease risk. Through a systematic review and meta-analysis, they found that the incidence of anti-NMDAR encephalitis varies among countries, with higher rates in Oceania and South America compared to Europe and North America. Regression models confirmed a strong negative correlation with latitude and seasonal analyses showed a peak of cases during warm months. Exposure-lag-response models revealed a positive correlation between extreme hot temperatures and disease incidence in France.
Article
Oncology
Tobias Kessler, Daniel Schrimpf, Laura Doerner, Ling Hai, Leon D. Kaulen, Jakob Ito, Martin van den Bent, Martin Taphoorn, Alba A. Brandes, Ahmed Idbaih, Julien Domont, Paul M. Clement, Mario Campone, Martin Bendszus, Andreas von Deimling, Felix Sahm, Michael Platten, Wolfgang Wick, Antje Wick
Summary: The EORTC-26101 study investigated the efficacy of combination therapy with bevacizumab and lomustine versus lomustine alone in progressive glioblastoma. Molecular data from DNA methylation arrays and panel sequencing were analyzed to assess prognostic biomarkers. The study found that MGMT promoter methylation and RTK1 classifier assignment were prognostic factors, while NF1 mutation may predict response to bevacizumab treatment.
CLINICAL CANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Federica Fabro, Trisha V. Kers, Kate J. Feller, Cecile Beerens, Ioannis Ntafoulis, Ahmed Idbaih, Maite Verreault, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H. M. Prehn, Annette T. Byrne, Alice C. O'Farrell, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Andreas Kremer, Romain Tching Chi Yen, Miao-Ping Chien, Martine L. M. Lamfers, Sieger Leenstra
Summary: Chemotherapy using temozolomide is the standard treatment for glioblastoma, but temozolomide resistance remains a challenge. This study reveals the association between resistance and heterogeneity in glioblastoma, and identifies distinct phenotypic behaviors and gene expressions in response to temozolomide. The adaptability and heterogeneity of glioblastoma cells contribute to their ability to survive and develop resistance mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Marta Maccari, Chooyoung Baek, Mario Caccese, Susanna Mandruzzato, Alba Fiorentino, Valeria Interno, Alberto Bosio, Giulia Cerretti, Marta Padovan, Ahmed Idbaih, Giuseppe Lombardi
Summary: Glioblastoma (GBM) is a common and aggressive brain tumor with poor treatment outcomes. Standard therapies have not been effective, leading to a growing interest in immunotherapic approaches. However, GBM is highly immunosuppressive, which may explain the failures of immunotherapy clinical trials. This review examines the current landscape of immunotherapy strategies in GBM, focusing on the challenge of immunoresistance and potential mechanisms to overcome it.
